Nearly 80% of clinical trials fail to enroll on time. Behind this number are delayed treatments and missed opportunities for patients. Too often, the terms friendly and patient-centric are used interchangeably. Friendliness—kind staff, a welcoming waiting room, simplified language—makes participation more pleasant, but true patient-centricity is something far deeper. It is a paradigm shift that…

Navigating the regulatory landscape is one of the most crucial, and often most complex, steps in bringing innovative allogeneic CAR-T therapies to market. For biotech companies pioneering the next wave of off-the-shelf treatments, having a dedicated, expert-led regulatory team—your “dream team”—can be the decisive factor that determines whether your therapy reaches patients swiftly or faces…

In the rapidly evolving landscape of cell therapy, particularly with the rise of allogeneic (“off-the-shelf”) CAR-T treatments, agility and expertise are no longer optional—they are essential. Traditional large CROs, while proven at scale, often fall short when it comes to the nuanced, high-stakes demands of pioneering therapies that are redefining medicine. That’s where CRO flexibility…

Choosing an adequate CRO for an allogeneic cell therapy trial is a critical decision that can determine the success or failure of a program. Allogeneic cell therapy is one of the most exciting frontiers in medicine, offering the promise of “off-the-shelf” treatments that could transform oncology and beyond, but this promise comes with an exceptionally…

The field of oncology is undergoing a dramatic transformation, driven by the rise of cell therapies. For years, the gold standard was autologous CAR-T therapy, a groundbreaking approach that uses a patient’s own modified immune cells to fight cancer. But while incredibly effective, this method is plagued by logistical and manufacturing hurdles. It’s a slow,…

Merging Science, Compliance, and Decades of Biosimilar Expertise Phase I clinical research is the foundation of every successful drug development program—determining a compound’s safety, pharmacokinetics (PK), and pharmacodynamics (PD) before moving forward into larger trials. At our state-of-the-art Phase I unit, located in the heart of a tertiary university hospital, we provide the ideal environment for conducting early-phase…

On 5–6 May, Basel buzzed with biotech brilliance as Swiss Biotech Days 2025 united over 3,000 innovators and investors from across theglobe. As a Swiss-headquartered CRO and proud member of the Swiss Biotech Association, Accelsiors was thrilled to dive into this dynamic event, now a cornerstone of the global biotech calendar. At our booth, we…

A New Era in Early-Phase Trials Early-phase clinical trials—particularly First-in-Human (FIH) and Phase I studies—are the backbone of drug development, determining whether a new treatment is safe, effective, and viable for further testing. Historically, these trials have been time-consuming, costly, and heavily reliant on trial-and-error dosing methods.  But now, biomarker-driven strategies, artificial intelligence (AI), and adaptive trial designs are…

This year, Accelsiors had the unique opportunity to participate in the Festival of Biologics USA, held at the San Diego Convention Center on April 23–24. With over 1,500 participants and exhibitors from around the world, the Festival was an inspiring experience, offering opportunities for growth, raising Accelsiors’ visibility, and establishing many valuable new connections. The…

The Role of Biomarkers in Accelerating Drug Development Imagine developing a new drug for Alzheimer’s disease (AD)—only to discover halfway through clinical trials that many participants didn’t actually have the (right) disease pathology. This costly mistake is exactly why biomarkersare reshaping neurodegenerative disease drug development.  Biomarkers in clinical trials help researchers:  As regulatory agencies like…